Search by Drug Name or NDC
NDC 68462-0295-10 Trandolapril and Verapamil Hydrochloride 2; 180 mg/1; mg/1 Details
Trandolapril and Verapamil Hydrochloride 2; 180 mg/1; mg/1
Trandolapril and Verapamil Hydrochloride is a ORAL TABLET, FILM COATED, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Glenmark Pharmaceuticals Inc., USA. The primary component is TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE.
MedlinePlus Drug Summary
The combination of trandolapril and verapamil is used to treat high blood pressure. It is a combination of two medications. It decreases certain chemicals that tighten the blood vessels, so blood flows more smoothly. It also relaxes your blood vessels so your heart does not have to pump as hard. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Related Packages: 68462-0295-10Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Trandolapril and Verapamil
Product Information
| NDC | 68462-0295 |
|---|---|
| Product ID | 68462-295_a3d55a5c-1f69-456d-a01a-60c18b186264 |
| Associated GPIs | 36991502700432 |
| GCN Sequence Number | 029251 |
| GCN Sequence Number Description | trandolapril/verapamil HCl TAB BP 24H 2 MG-180MG ORAL |
| HIC3 | A4K |
| HIC3 Description | ACE INHIBITOR-CALCIUM CHANNEL BLOCKER COMBINATION |
| GCN | 32111 |
| HICL Sequence Number | 012230 |
| HICL Sequence Number Description | TRANDOLAPRIL/VERAPAMIL HCL |
| Brand/Generic | Generic |
| Proprietary Name | Trandolapril and Verapamil Hydrochloride |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Trandolapril and Verapamil Hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 2; 180 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE |
| Labeler Name | Glenmark Pharmaceuticals Inc., USA |
| Pharmaceutical Class | Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhi |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA079135 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 68462-0295-10 (68462029510)
| NDC Package Code | 68462-295-10 |
|---|---|
| Billing NDC | 68462029510 |
| Package | 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (68462-295-10) |
| Marketing Start Date | 2015-02-25 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |